Brainomix

Executive Summary

Brainomix is a UK-based AI-powered medtech company specializing in neuroimaging software for stroke diagnosis and treatment. Founded in 2010 and headquartered in Oxford, the company has developed proprietary platforms—e-ASPECTS and e-CTA—that provide rapid, quantitative analysis of brain scans to support clinical decision-making in time-critical neurological emergencies. By enabling faster and more accurate assessments, Brainomix’s technology aims to improve patient outcomes, reduce treatment delays, and streamline workflows in stroke centers. The company has achieved commercial traction, with its products deployed across multiple healthcare systems, and continues to expand its footprint in global markets. As a commercial-stage enterprise with a validated AI platform, Brainomix is well-positioned to capitalize on the growing adoption of AI in radiology and neurology. Its solutions address a significant unmet need in stroke care, where every minute saved can dramatically affect patient recovery. The company’s focus on regulatory approvals, clinical evidence generation, and strategic partnerships positions it for sustained growth. With the stroke AI market expected to expand rapidly, Brainomix’s established products and pipeline of innovations make it a compelling player in the digital health space.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for e-CTA Platform in the U.S.75% success
• Q4 2026Announcement of Major Hospital Network Deployment in Europe65% success
• Q1 2027Publication of Landmark Clinical Study Validating e-ASPECTS Outcomes80% success